AX-2026-042018 · GHRP-6 · AMB lot AMB-2603-S5667

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	99.56	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.44	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — oxidised Trp (+16 Da)	0.30	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	872.4446	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	872.4244	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-23.2	ppm	± 15	FAIL
Total peptide content	by difference from the gravimetric mass balance	86.92	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	86.54	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	11.36	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	9.831	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	98.3	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	6.57	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.74	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.77	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White cake, partial shrinkage from vial wall	—	white to off-white intact cake	FAIL
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.20	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 25 min gradient	7.26	min	7.15 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.08	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	71,292	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Trp]-epimer	0.90	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 71,292, and skew follows the reported asymmetry factor of 1.08. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.30 % impurity against a 99.56 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	GHRP-6 — main peak	7.26	4,838,925	99.56	—
2	oxidised Trp (+16 Da)	6.98	14,581	0.30	+15.995
3	[D-Trp]-epimer	7.16	3,888	0.08	0.000
4	bis-oxidised Trp (+32 Da)	6.78	1,458	0.03	+31.990
5	des-Lys (−128 Da)	7.08	1,458	0.03	-128.095
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 872.4446 Da, computed from C46H56N12O6. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 872.4244 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	437.2296	437.2195	-0.0101	56.0
1+	873.4519	873.4317	-0.0202	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	6.57
Counter-ion (acetate)	ion chromatography	5.74
Residual solvent + inorganic residue	estimated	0.77
Total peptide content	by difference	86.92
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.54	99.56	divergence +0.17 pp vs batch median
Total impurities (% area)	0.46	0.44
Largest single impurity (% area)	0.30	0.30
Water (%)	4.7	6.57
Counter-ion (%)	not stated	5.74
Peptide content (%w/w)	90.5	86.92
Endotoxin (EU/mg)	0.39	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 30 d) → laboratory (hand-carried, 11 d) → assay.
Assay date: 18 Jul 2026
Submitted to the index: 25 Jul 2026
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

quarter_over_quarter25 Jul 2026

Single records do not establish trends. Where this supplier's quarterly medians are stable across four quarters, a result like this reads as the process rather than the draw — and the timeline page is where to check that.

mass_defect25 Jul 2026

Mass-defect reasoning narrows this quickly. Very few plausible modifications of GHRP-6 would produce a shift in the direction and magnitude observed, and the ones that would are all in the named-impurity table.

bootstrap_ci25 Jul 2026

One measurement, one instrument, one day. There is no interval around -23.2 ppm on this record and treating it as a point estimate overstates what a single determination supports.

valley_drop25 Jul 2026

The reported figure derives from the plate count and the retention gap, via the pharmacopoeial form with the sum of both peak widths in the denominator. It is a calculated quantity, not a measured one, and it inherits the plate count's uncertainty.

Section 7

Related records

Same batch — lot AMB-2603-S5667 n=9

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042011	AMB-2603-S5667	Medutest	2026-Q3	99.37	6.38	—	Buyer-sourced	1	MARGINAL
AX-2026-042012	AMB-2603-S5667	Janoshik	2026-Q3	99.37	5.90	88.8	Laboratory-retained	1	MARGINAL
AX-2026-042013	AMB-2603-S5667	Kestrel	2026-Q3	99.93	5.75	—	Buyer-sourced	0	PASS
AX-2026-042014	AMB-2603-S5667	PeptideMeter	2026-Q3	99.24	6.62	—	Buyer-sourced	0	PASS
AX-2026-042015	AMB-2603-S5667	Janoshik	2026-Q3	99.54	6.44	97.1	Buyer-sourced	0	PASS
AX-2026-042016	AMB-2603-S5667	PeptideMeter	2026-Q3	99.34	6.58	97.3	Buyer-sourced	0	PASS
AX-2026-042017	AMB-2603-S5667	Medutest	2026-Q3	99.76	6.42	97.4	Buyer-sourced	0	PASS
AX-2026-042019	AMB-2603-S5667	PeptideMeter	2026-Q3	98.81	6.11	—	Buyer-sourced	0	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent GHRP-6 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042012	AMB	AMB-2603-S5667	Janoshik	2026-Q3	99.37	5.90	88.8	Laboratory-retained	1	MARGINAL
AX-2026-042528	HJ	HJ-2603-R5329	VendorInvestigate	2026-Q3	98.69	1.87	95.8	Buyer-sourced	0	FAIL
AX-2026-042015	AMB	AMB-2603-S5667	Janoshik	2026-Q3	99.54	6.44	97.1	Buyer-sourced	0	PASS
AX-2026-042526	HJ	HJ-2603-R5329	Medutest	2026-Q3	99.37	3.06	—	Laboratory-retained	0	PASS
AX-2026-042527	HJ	HJ-2603-R5329	VendorInvestigate	2026-Q3	99.21	2.77	93.2	Buyer-sourced	0	PASS
AX-2026-042525	HJ	HJ-2603-R5329	Janoshik	2026-Q3	99.52	3.24	92.0	Buyer-sourced	0	PASS
AX-2026-042013	AMB	AMB-2603-S5667	Kestrel	2026-Q3	99.93	5.75	—	Buyer-sourced	0	PASS
AX-2026-042017	AMB	AMB-2603-S5667	Medutest	2026-Q3	99.76	6.42	97.4	Buyer-sourced	0	PASS

Other recent AMB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042002	Semaglutide	AMB-2607-N6274	VendorInvestigate	2026-Q3	98.23	6.37	97.1	Buyer-sourced	1	MARGINAL
AX-2026-042012	GHRP-6	AMB-2603-S5667	Janoshik	2026-Q3	99.37	5.90	88.8	Laboratory-retained	1	MARGINAL
AX-2026-041974	Tirzepatide	AMB-2603-C5112	Nordanalyt	2026-Q3	98.20	3.41	—	Buyer-sourced	0	PASS
AX-2026-041975	Tirzepatide	AMB-2603-C5112	Medutest	2026-Q3	97.88	3.45	106.9	Laboratory-retained	0	PASS
AX-2026-042005	Semaglutide	AMB-2607-N6274	PeptideMeter	2026-Q3	98.09	6.48	98.6	Buyer-sourced	1	MARGINAL
AX-2026-042008	Epitalon	AMB-2602-Y6433	Janoshik	2026-Q3	99.30	8.75	105.1	Buyer-sourced	0	PASS
AX-2026-042021	TB-500	AMB-2602-P5987	VendorInvestigate	2026-Q3	99.86	4.79	101.4	Buyer-sourced	0	PASS
AX-2026-042015	GHRP-6	AMB-2603-S5667	Janoshik	2026-Q3	99.54	6.44	97.1	Buyer-sourced	0	PASS